Treatment of Diabetic Foot with Heberprot-P

CTFMT highliths the Heberprot-P program in Cuba represents a significant breakthrough in the treatment of diabetic foot ulcers, a common and severe complication of Diabetes Mellitus. This unique medication has been developed to address the challenges posed by diabetic foot ulcers and has garnered recognition in multiple countries for its effectiveness in reducing the risk of amputations and improving the quality of life for patients.

Key Highlights of the Heberprot-P® Program:

1. Diabetic Foot Ulcer Treatment: Diabetic foot ulcers are a serious complication of Diabetes Mellitus, affecting a significant proportion of diabetic patients. These ulcers can lead to severe tissue damage, infections, and even amputations. The Heberprot-P® program provides a targeted and innovative solution to address this critical medical issue.
2. Reduced Amputation Risk: One of the most remarkable achievements of Heberprot-P® is its ability to significantly reduce the risk of amputations in diabetic patients with foot ulcers. Studies have shown that the medication can lead to a nearly 78 percent reduction in the relative risk of amputations. This is a crucial advancement in improving the outcomes and quality of life for patients.
3. Unique Medicament: Heberprot-P® is a freeze-dried, sterile product that contains Recombinant Human Epidermal Growth Factor. This innovative formulation stimulates progressive and continuous granulation and cicatrization of diabetic foot ulcers. By promoting wound healing, it helps to prevent the need for more invasive interventions, such as debridement and surgical procedures.
4. Comprehensive Program: The Heberprot-P® program includes a well-structured approach to patient care. It starts with an initial assessment by a doctor, followed by nursing attention and a comprehensive medical history review. Medical research is conducted to tailor the treatment to the patient’s condition. The application of Heberprot-P® involves administering 15 vials of the medication, contributing to wound healing and improved outcomes. The program concludes with a discharge medical summary.

Advantages of Using Heberprot-P®:

• Stimulated Healing: The medication’s unique formulation promotes granulation and cicatrization of diabetic foot ulcers, supporting natural wound healing processes.
• Reduced Interventions: By accelerating wound healing, Heberprot-P® reduces the need for frequent debridement and surgical interventions, enhancing patient comfort and recovery.
• Reduced Complications: Faster wound healing contributes to reduced complications such as gangrene, infections, and over-infection, which can lead to more severe outcomes.
• Cost-Effectiveness: The program’s ability to reduce the need for amputations and hospital stays results in reduced healthcare costs and improved resource utilization.
• Improved Quality of Life: By preventing amputations and promoting healing, Heberprot-P® contributes to a higher quality of life and functional recovery for patients.

The Heberprot-P® program exemplifies Cuba’s commitment to innovative healthcare solutions and underscores the significant impact that targeted therapies can have on improving patient outcomes and well-being.